Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42

Background: Amyloid beta 1–43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer’s disease (AD). We have investigated cerebrospinal fluid (CSF) levels of Aβ43 in patients with early-onset AD in contrast to levels in late-onset AD. For comparison, in addition to the ‘core’ biomarker...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Aging Neurosci
Autores principales: Lauridsen, Camilla, Sando, Sigrid B., Møller, Ina, Berge, Guro, Pomary, Precious K., Grøntvedt, Gøril R., Salvesen, Øyvind, Bråthen, Geir, White, Linda R.
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2017
Materias:
Neuroscience
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5487529/
https://ncbi.nlm.nih.gov/pubmed/28701950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnagi.2017.00210
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares